Other Events ·
Perspective Therapeutics updates corporate presentation highlighting clinical-stage radiopharmaceutical pipeline
CATXPerspective Therapeutics, Inc.
On October 1, 2026, Perspective Therapeutics filed a Form 8-K to update its corporate presentation. The filing incorporates by reference Exhibit 99.1, which details the company's next-generation radiopharmaceutical programs targeting neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and advanced solid tumors (PSV359). The presentation outlines ongoing Phase 1/2a trials, preliminary anti-tumor activity, and a $45 billion+ addressable market. Perspective Therapeutics operates in the biotechnology sector, focusing on targeted oncology therapies using radiopharmaceuticals.